Application of CST6 as early diagnosis marker for brain metastasis of lung cancer

By detecting CST6 protein or gene levels and combining it with diagnostic models, the insufficient sensitivity and screening challenges in the early diagnosis of lung cancer brain metastases have been addressed, enabling early warning and dynamic monitoring of high-risk groups, thus improving the accuracy and safety of diagnosis.

CN121522166APending Publication Date: 2026-02-13SOUTHERN MEDICAL UNIVERSITY
0 Cites 0 Cited by

Patent Information

Application Number
CN202511443347.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2025-10-10
Publication Date
2026-02-13

AI Technical Summary

Technical Problem

Current imaging techniques lack sensitivity in the early diagnosis of lung cancer brain metastases, are unable to effectively detect micrometastases, and lack non-invasive, low-cost screening methods for high-risk populations, leading to missed opportunities for treatment intervention.

Method used

Using CST6 as a biomarker, diagnostic models are constructed by detecting the CST6 protein or gene levels in serum or cerebrospinal fluid, combined with algorithms such as logistic regression and linear discriminant analysis, and early diagnosis and risk prediction are performed using methods such as ELISA and immunofluorescence assay.

Benefits of technology

It enables early diagnosis and warning, significantly advances the timing of intervention, and the detection method is minimally invasive and safe, suitable for dynamic monitoring of high-risk groups, and improves the sensitivity and specificity of diagnosis.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention belongs to the technical field of biological medicine, and particularly relates to application of CST6 as a lung cancer brain metastasis early diagnosis marker. The core of the invention is to confirm that CST6 is used as a marker for early diagnosis and prediction of brain metastasis of lung cancer for the first time. In experimental verification, the CST6 protein expression quantity of the lung cancer cell strain H1975-BrM with high brain metastasis potential is remarkably higher than that of a common cell strain, an animal model further shows that overexpression of CST6 can promote formation of brain metastasis, and knock-down expression can inhibit metastasis capacity; clinical sample analysis shows that the serum CST6 concentration of brain metastasis patients is far higher than that of non-metastasis patients and healthy people, and the diagnostic value of CST6 is supported. In the aspect of diagnosis efficiency, the area under the ROC curve of the serum CST6 reaches 0.848, and high accuracy is shown. On the whole, the clinical blank is filled, and a reliable tool is provided for non-invasive lung cancer brain metastasis risk management.
Need to check novelty before this filing date? Find Prior Art